A large Mendelian randomization study in East Asian biobank participants found that genetically proxied GLP1R agonism reduces type 2 diabetes risk and lowers glucose levels without changing body-mass index, adiposity, or cardiovascular outcomes. The analysis supports a separation between glycemic effects and weight effects for GLP1R pathway modulation in the population-level genetic setting. Researchers reported consistent associations with diabetes risk and glycemic biomarkers, while cardiometabolic endpoints did not move in the same direction. For drug developers and payers tracking incretin biology, the study strengthens the case that GLP1R-targeting therapies can be evaluated for diabetes benefit even when weight loss is not the dominant mechanism in a given population.